Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Arm 1 - DehydraTECH-CBD alone
DehydraTECH-CBD alone · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 - DehydraTECH-CBD alone | EXPERIMENTAL | - |
| Arm 2 - DehydraTECH-semaglutide alone | EXPERIMENTAL | - |
| Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide | EXPERIMENTAL | - |
| Arm 4 - Rybelsus medication (semaglutide) alone as a positive control. | ACTIVE_COMPARATOR | - |
| Arm 5- DehydraTECH Tirzepatide | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Arm 1 - DehydraTECH-CBD alone | DRUG | Dose: 250 mg CBD twice daily (500 mg/day) for 12 weeks. Route of administration: Oral Dosage form: Capsule |
| Arm 2 - DehydraTECH-semaglutide alone | DRUG | Dose: 3.5 mg once daily for 4 weeks, ascending to 7 mg once daily for the remaining 8 weeks. Route of administration: Oral Dosage form: Capsule |
| Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide | DRUG | DehydraTECH-CBD dosing = 250 mg twice daily for 12 weeks. \- DehydraTECH-semaglutide = 3.5 mg once daily for 12 weeks Route of administration: Oral Dosage form: Capsule |
| Arm 4 - Rybelsus medication (semaglutide) alone | DRUG | Normal clinical dose of 3.0 mg once daily for 4 weeks, ascending to 7.0 mg once daily for the remaining 8 weeks. Route of administration: Oral Dosage form: Capsule |
| Arm 5- Tirzepatide | DRUG | Tirzepatide arm - 20mg for 4 weeks and then 40mg for 8 weeks |
Inclusion criteria: 1. Clinically diagnosed as overweight or obese, with or without pre- or Type 2 diabetes with residual islet cell function. 2. For participants with pre- or Type 2 diabetes: diet controlled or receiving oral anti-diabetic treatment (metformin or other biguanides and/or sulphonylu...
DehydraTECH-CBD alone is an investigational drug candidate developed by Lexaria Bioscience Corp. (ticker LEXX) that combines cannabidiol with the company's DehydraTECH delivery technology. It was studied as a standalone treatment arm in a Phase 1 clinical trial in overweight or obese, pre-diabetic and Type 2 diabetic participants.
DehydraTECH-CBD alone was evaluated for use in overweight or obese adults who were pre-diabetic or had Type 2 diabetes. The Phase 1 trial assessed its safety, efficacy and pharmacokinetics, both alone and in comparison with DehydraTECH-GLP1 agonists and combinations of the two.
DehydraTECH-CBD alone is developed by Lexaria Bioscience Corp., which trades under the ticker LEXX. Lexaria is the company behind the DehydraTECH drug delivery platform used in this cannabidiol formulation.
DehydraTECH-CBD alone has been studied in a Phase 1 clinical trial. It is an investigational drug candidate and is not approved by the FDA. The Phase 1 trial has been completed.
DehydraTECH-CBD alone was evaluated in the Phase 1 trial NCT06648031, titled Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH-CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants. The trial enrolled 148 participants in Australia and has been completed.
Yes. DehydraTECH-CBD alone is also referred to as Arm 1 - DehydraTECH-CBD alone. This name reflects its role as the standalone cannabidiol treatment arm within the Phase 1 trial comparing DehydraTECH-CBD, DehydraTECH-GLP1 agonists, and their combinations.